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required transfusion. There was 1 maternal death from valve thrombosis (in
the Enoxaparin-treated group). The incidence of maternal complications was
similar between the 2 groups. 2 cases ended in early miscarriage, and 5 cases
ended in intrauterine fetal death. The frequencies of fetal complications, live
born and healthy babies were similar between the 2 groups.
Regarding the efficacy and safety of antithrombotic treatment in preg-
nant women with prosthetic heart valves, Enoxaparin treatment during the
first trimester is an acceptable regimen. These patients require close sur-
veillance for bleeding and thrombotic complications within a multidisci-
plinary setting
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Background: mitral stenosis is characterized by pathological remodelling
of valvular tissue but the molecular effectors involved in these processes are
not well known. The role of matrix metalloproteinase MMP-9, MMP-3, and
tissue inhibitor of matrix metalloproteinase (TIMP)-1 and TIMP-2 are investi-
gated here.
Subjects and methods: 235 patients with mitral stenosis and 150 healthy
control subjects were recruited. MMP-9, MMP-3, TIMP-1 and TIMP-2 levels
in plasma were measured using an ELISA assay. 
Results: The plasma concentrations of MMP-3, TIMP-1 were signifi-
cantly lower in patients compared with control group. MMP-9 rate is sig-
nificantly increased in patients with mitral stenosis. In men, a negative
correlation was observed between calcification degree and rate of MMP-9
(r=–0.484, p<0.001) and positive with MMP-3 (r=0.588, p<0.001). In
women, positive correlation was found between MMP-9 and mitral area
(r=0.387, p=0.002) and also between MMP3 and calcification degree
(r=0.603, p<0.001). 
Conclusion: This study demonstrates the involvement of the MMP/TIMP
system in ECM remodelling of stenosis mitral. We have shown a difference in
level of MMP- 9 between the mitral stenosis and the control. MMP9 was
involved in calcification of the mitrale valve. 
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Background: the diagnosis of infected protheses in patients with long
standing fever is difficult, challenging and has major impact on the manage-
ment. 
Aim: Since 18-Fluo Desoxyglucose positron emission tomography per-
formed together with computerized tomography (FDG PET-CT) has a role in
the diagnosis and localization of infection; we evaluated its value in the diag-
nosis of infected prostheses, correlating its results with medical workup, echo-
cardiogram and dedicated CT.
Patients: Fourteen patients (pts) with cardiovascular prostheses (seven with
a pacemaker, four with vascular grafts, two with pulmonary stent and one with
mitral valve prosthesis were hospitalized for prolonged fever.
Methods: All pts received antibiotics and underwent repeated medical
workup. Eight of the 14 pts had a proven bacteriemia. Transthoracic and tran-
soesophagial echocardiogram was performed as well as CT, for most of them.
FDG PET-CT was performed in all of them, following injection of 370 MBq
of F-18 FDG. All patients were normoglycemic at the time of injection.
Results of the FDG PET-CT were compared with other diagnostic modalities
and clinical follow up.
Results: In the 7 pts with pacemaker, FDG PET-CT was positive in 4,
echo in 2/4. IN 3/4 the device was removed. A new pacemaker was
implanted for two patients after few weeks. FEG PET-CT was negative in
3/7 pts with 1 positive, 1 negative and 1 intermediate results. All patients
with vascular graft had positive FDG PET-CT scan and only one had a
positive echocardiogram. This patient had a surgical proven abscess. Two
pts with pulmonary stent had a positive FDG PET-CT scan and 1 positive
echo. In this patient the stent extracted was infected. FDG PET-CT and
echo was negative in the patient with mitral prosthesis.Conventional CT
was positive in only 1 patient. Twelve pts return to normal including all
the patients after prostheses extraction except one who died during graft
replacement.
Conclusion: FDG PET -CT is a useful tool for the diagnosis of infected
cardiovascular prosthesis and is more accurate than stand alone CT. Correla-
tion of the clinical, echo and FDG PET CT findings is crucial for the thera-
peutic decision. 
0350
Prevalence and management of cardiovascular diseases in patients
with hemophilia
Lucie Bocquillon (1), Marie Francoise Thiercelin (2), Sophie Voisin (3),
Eric Ouhayoun (4), Alessandra Bura Riviere (5), Ségolène Claeyssens (2),
Thibault Lhermusier (1)
(1) CHU Toulouse Rangueil, Cardiologie, Toulouse, France – (2) CHU
Toulouse Purpan, Centre Régional Hémophilie, Toulouse, France – (3)
CHU Toulouse Rangueil, Hémostase, Toulouse, France – (4) CHU Tou-
louse Purpan, Médecine nucléaire, Toulouse, France – (5) CHU Toulouse
Rangueil, Médecine vasculaire, Toulouse, France
Introduction: The emergence of new herapies based on enhanced pre-
vention and treatment of viral diseases led to a significant improvement in
hemophiliacs’ life expectancy. Consequently, they are currently exposed to
cardiovascular diseases and candidates for antithrombotic treatments. The
benefits of antithrombotic therapy have not been demonstrated for this pop-
ulation and abnormal blood crasis may also provide a degree of antithrom-
botic protection. In this study, we aim to assess the prevalence of
cardiovascular disease and cardiovascular risk factors in patients with
hemophilia, but also collect data concerning the management of these dis-
eases. 
Methods: This study prospective, observational and monocentric was con-
ducted in a cohort of patients over 50 year old hemophiliacs followed at the
Regional Center for Hemophilia Midi Pyrénées. Patients were considered eli-
gible if their cardiovascular risk was moderate to high according to the
SCORE scale. A cardiovascular screening was performed including assess-
ment of risk factors and detection of peripheral and coronary atheromatous
plaque.
Results: 45 patients were enrolled from december 2010 to january 2013,
including 22 with minor hemophilia; 15 with moderate hemophilia; and 8
severe hemophiliacs. Monitoring was conducted until January 2014. 47% of
the patients (10 patients) had a very high cardiovascular risk. For 21 patients
(46.7%), the screening led to change cardiovascular medications or to propose
invasive treatment. Anti thrombotic treatment was prescribed to 11 patients.
3 patients were treated with double platelet anti-aggregation; 7 with single
platelet anti-aggregation and 1 patient with Vitamine K antagonists. No major
bleedings were reported. 
Conclusion: The prevalence of cardiovascular risk factors and of cardio-
vascular disease in patients with hemophilia is not negligible. Based on a per-
sonalized approach, antithrombotic therapies might be prescribed without
major bleeding complications. 
